ODAC recommends approval of melanoma drug, renal cell carcinoma drug - HemOncToday PDF Print
HemOncTodayThe panel also voted unanimously that the benefit-risk profile of pazopanib is acceptable for patients with advanced renal cell carcinoma.

... read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.